Advertisements


Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 17th, 2018

Cytokinetics announces data from Phase 2 clinical study of Reldesemtiv in SMA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 17th, 2018

Celsion announces publication of ThermoDox Phase I clinical study results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2018

Biotech ETFs Surge on Biogen"s Positive Drug Trial Result

Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment. Biogen Inc. BIIB was a star performer in Friday’s trading session, as the stock rallied as much as 23.1% but closed a l.....»»

Category: worldSource: nytJul 9th, 2018

Pulmatrix announces publication of data from Phase 1 study of PUR0200

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Allergan announces "positive" Phase 3 clinical data for Bimatoprost SR implant

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

Agios Pharmaceuticals announces new data from ivosidenib Phase 1 study at ASCO

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2018

Roche (RHHBY) Announces Positive Data on Hemophilia Drug

Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio. Roche RHHBY announced full results from the phase III study, HAVEN 3, evaluating haemo.....»»

Category: dealsSource: nytMay 21st, 2018

Precigen announces first patient dosed in Phase 1 clinical study of INXN-4001

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 21st, 2018

The Medicines Co. announces inclisiran data from ORION-1 Phase II study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 7th, 2018

Intercept Reports Phase III Sub-Study Liver Biopsy Data

Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patien.....»»

Category: worldSource: nytApr 16th, 2018

NewLink announces data from Phase 1 study of Indoximod in combo therapies

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2018

Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up

Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity. Shares of .....»»

Category: dealsSource: nytApr 11th, 2018

Advaxis shares rise 68% after FDA lifts clinical hold on its drug trial

Shares of the biotech company Advaxis Inc. surged 68% in premarket trade on Friday after the Food and Drug Administration lifted a clinical hold on the company's phase 1/2 study for a cancer drug combination. The clinical hol.....»»

Category: topSource: marketwatchJul 13th, 2018

Mid-Afternoon Market Update: Dow Up Over 200 Points; Zogenix Shares Gain On Positive Phase 3 Data In Dravet Syndrome Study

Toward the end of trading Thursday, the Dow traded up 0.88 percent to 24,918.80 while the NASDAQ climbed 1.19 percent to 7,808.43. The S&P also rose, gaining 0.81 percent to 2,796.34. read more.....»»

Category: blogSource: benzingaJul 12th, 2018

Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study

Zogenix, Inc. read more.....»»

Category: blogSource: benzingaJul 12th, 2018

resTORbio Spikes Higher Following Positive Phase 2 Data

resTORbio, Inc. (NASDAQ: TORC) announced Wednesday its TORC1 inhibitor treatment demonstrated targeted improvements in a Phase 2a clinical trial. read more.....»»

Category: blogSource: benzingaJul 11th, 2018

Achillion"s 3rd Factor D Inhibitor Enters Clinical Studies

Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor. Achillion Pharmaceuticals, Inc. ACHN announced that it has initiated a phase I study on its next-generation.....»»

Category: personnelSource: nytJul 11th, 2018

Scynexis announces results from Phase 2b study evaluating oral SCY-078

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2018

VIVUS announces "positive" results from Phase 1 clinical trial of VI-0106

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2018

Realm Therapeutics announces publication of pre-clinical study of PR022

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2018